JP2018513117A - 眼科用組成物およびその使用方法 - Google Patents

眼科用組成物およびその使用方法 Download PDF

Info

Publication number
JP2018513117A
JP2018513117A JP2017546870A JP2017546870A JP2018513117A JP 2018513117 A JP2018513117 A JP 2018513117A JP 2017546870 A JP2017546870 A JP 2017546870A JP 2017546870 A JP2017546870 A JP 2017546870A JP 2018513117 A JP2018513117 A JP 2018513117A
Authority
JP
Japan
Prior art keywords
corneal
composition
dexamethasone
cornea
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017546870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513117A5 (https=
Inventor
グリーン、コリン
アン グリーン、キャロル
アン グリーン、キャロル
シャーウィン、トレバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of JP2018513117A publication Critical patent/JP2018513117A/ja
Publication of JP2018513117A5 publication Critical patent/JP2018513117A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Eyeglasses (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017546870A 2015-03-05 2016-03-04 眼科用組成物およびその使用方法 Pending JP2018513117A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ705727 2015-03-05
NZ70572715 2015-03-05
PCT/NZ2016/050033 WO2016140581A1 (en) 2015-03-05 2016-03-04 Ophthalmic compositions and methods of use therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021011148A Division JP2021091688A (ja) 2015-03-05 2021-01-27 眼科用組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2018513117A true JP2018513117A (ja) 2018-05-24
JP2018513117A5 JP2018513117A5 (https=) 2019-04-11

Family

ID=56848288

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017546870A Pending JP2018513117A (ja) 2015-03-05 2016-03-04 眼科用組成物およびその使用方法
JP2021011148A Pending JP2021091688A (ja) 2015-03-05 2021-01-27 眼科用組成物およびその使用方法
JP2023030945A Active JP7641650B2 (ja) 2015-03-05 2023-03-01 眼科用組成物およびその使用方法
JP2024218517A Pending JP2025032318A (ja) 2015-03-05 2024-12-13 眼科用組成物およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021011148A Pending JP2021091688A (ja) 2015-03-05 2021-01-27 眼科用組成物およびその使用方法
JP2023030945A Active JP7641650B2 (ja) 2015-03-05 2023-03-01 眼科用組成物およびその使用方法
JP2024218517A Pending JP2025032318A (ja) 2015-03-05 2024-12-13 眼科用組成物およびその使用方法

Country Status (11)

Country Link
US (2) US10842850B2 (https=)
EP (1) EP3265096B9 (https=)
JP (4) JP2018513117A (https=)
KR (1) KR102450674B1 (https=)
CN (1) CN107530360B (https=)
AU (1) AU2016226699B2 (https=)
ES (1) ES2952700T3 (https=)
MY (1) MY186271A (https=)
SG (1) SG11201708114SA (https=)
TW (1) TWI747816B (https=)
WO (1) WO2016140581A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022125941A (ja) * 2021-02-17 2022-08-29 株式会社ティ・エム・ディ コンタクトレンズ

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
ES2986057T3 (es) 2012-03-29 2024-11-08 Epion Therapeutics Inc Composiciones y métodos para tratar o prevenir enfermedades asociadas al estrés oxidativo
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
KR102706856B1 (ko) 2015-07-21 2024-09-19 아베드로 인코퍼레이티드 광증감제로 눈을 치료하기 위한 시스템 및 방법
CN110092816B (zh) * 2018-01-29 2023-08-01 上海市第一人民医院 预防和治疗纤维化的小分子多肽及其应用
US20210060017A1 (en) * 2018-02-27 2021-03-04 Shilpa Medicare Ltd Methotrexate ophthalmic solution
CN108728418A (zh) * 2018-06-19 2018-11-02 新乡医学院 一种鸡胚中枢神经系统单个神经元动态研究模型的制备方法及应用
WO2020092897A1 (en) * 2018-11-02 2020-05-07 Senseonics, Incorporated Drug eluting matrix on analyte indicator
GB201820021D0 (en) * 2018-12-07 2019-01-23 Univ Birmingham Ocular hydrogel compositions
JP2025529178A (ja) 2022-09-01 2025-09-04 オプティファイ・セラピューティクス・アクティエンゲゼルシャフト 眼科用組成物
EP4687950A1 (en) * 2023-03-30 2026-02-11 Cetel Scientific LLC Amniotic and chorionic collagen for ocular surface healing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786812A (en) * 1972-03-10 1974-01-22 C Neefe Contact lens for olar drug delivery
US4177268A (en) 1973-05-30 1979-12-04 Jouveinal S.A. Method of alleviating inflammation by administration of dexamethasone derivatives
AU660635B2 (en) * 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
US5411940A (en) 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
CN1770976A (zh) 2003-02-13 2006-05-10 人类起源公司 利用脐带血治疗患有疾病、紊乱或状况的个体的用途
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2007099337A1 (en) 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US8110655B2 (en) 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
AU2007319811A1 (en) 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
JP2011505409A (ja) 2007-12-04 2011-02-24 ノバガリ ファーマ エスエー パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
EP2249921B1 (en) 2008-02-25 2020-06-17 Eyegate Pharmaceuticals, Inc. Enhanced delivery of dexamethasone phosphate to ocular tissues through iontophoresis
EP2370054B1 (en) * 2008-12-11 2015-10-07 Massachusetts Institute of Technology Contact lens drug delivery device
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
WO2012088044A2 (en) 2010-12-20 2012-06-28 James Mcmillan Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
KR101518370B1 (ko) 2013-06-25 2015-05-07 가톨릭대학교 산학협력단 Il-10 생성 조절 t세포로의 분화 유도용 조성물
CN104548210A (zh) 2014-12-13 2015-04-29 浙江大学 含地塞米松转化生长因子的可控缓释plga微球及制备
TWI747816B (zh) 2015-03-05 2021-12-01 紐西蘭商奧克蘭聯合服務有限公司 眼用組合物用於製備藥物的用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124392A (en) * 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIABETES, vol. 63, JPN6019051318, 2014, pages 715 - 727, ISSN: 0004185193 *
INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 54, no. 13, JPN6019051315, 2013, pages 5250, ISSN: 0004483811 *
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 83, no. 3, JPN6019051316, 2007, pages 779 - 786, ISSN: 0004483812 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022125941A (ja) * 2021-02-17 2022-08-29 株式会社ティ・エム・ディ コンタクトレンズ

Also Published As

Publication number Publication date
US11938168B2 (en) 2024-03-26
AU2016226699B2 (en) 2020-10-22
NZ735959A (en) 2021-10-29
CN107530360A (zh) 2018-01-02
US20220047676A1 (en) 2022-02-17
WO2016140581A1 (en) 2016-09-09
MY186271A (en) 2021-07-01
KR20170132197A (ko) 2017-12-01
EP3265096B1 (en) 2023-06-07
JP7641650B2 (ja) 2025-03-07
TWI747816B (zh) 2021-12-01
TW201639592A (zh) 2016-11-16
US10842850B2 (en) 2020-11-24
KR102450674B1 (ko) 2022-10-04
JP2025032318A (ja) 2025-03-11
US20180050088A1 (en) 2018-02-22
ES2952700T3 (es) 2023-11-03
JP2023066425A (ja) 2023-05-15
EP3265096C0 (en) 2023-06-07
JP2021091688A (ja) 2021-06-17
AU2016226699A1 (en) 2017-10-26
EP3265096A1 (en) 2018-01-10
CN107530360B (zh) 2021-09-17
EP3265096A4 (en) 2018-10-24
SG11201708114SA (en) 2017-11-29
EP3265096B9 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
JP7641650B2 (ja) 眼科用組成物およびその使用方法
Lin et al. Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction
Zhang et al. Effects of mesenchymal stem cells and their exosomes on the healing of large and refractory macular holes
Borderie et al. Long-term results of cultured limbal stem cell versus limbal tissue transplantation in stage III limbal deficiency
Xiong et al. Stem cell transplantation rescued a primary open-angle glaucoma mouse model
JP2017522016A (ja) 培養哺乳動物輪部幹細胞、その産生方法及びその使用
KR20120102709A (ko) 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
EP3986430B1 (en) Methods of promoting vasculogenesis
US20180353645A1 (en) Lens regeneration using endogenous stem/progenitor cells
Zhu et al. Ultrasound targeted microbubble destruction promotes the therapeutic effect of HUMSC transplantation on glaucoma-caused optic nerve injury in rabbits
Klintworth et al. Corneal dystrophies and keratoconus
JP2019524688A (ja) 前駆細胞を用いた網膜血管疾患の治療
Angunawela et al. Live or let die: epithelial flap vitality and keratocyte proliferation following LASEK and epi-LASIK in human donor and porcine eyes
NZ735959B2 (en) Ophthalmic compositions and methods of use therefor
US20210189334A1 (en) Corneal Epithelial Cells and Their Products for Treating Corneal Diseases
Loureiro et al. Analysis of different conditioned media secreted by limbal progenitor cells in the modulation of corneal healing
Yao et al. Effect of diclofenac sodium combined with nuclear rotation on the prevention of posterior capsule opacification: two-year follow-up
Zhang et al. Autologous glueless simple oral mucosal transplantation for the repair of limbal stem cell deficiency ocular surface in a rabbit model
Zhang et al. Human Umbilical Cord Mesenchymal Stem Cell-derived Exosomal miR-27b Attenuate Subretinal Fibrosis via Suppressing Epithelial-mesenchymal Transition by Targeting HOXC6
WO2024172043A1 (ja) 網膜色素上皮裂孔の治療薬
WO2025151812A1 (en) Processes for making and using a mesenchyme stem cell secretome for limbal stem cell deficiency (lscd) treatment
Chang Analysis of Stem Cells and Wound Healing in the Human Cornea
Ozek et al. Efeito do agente bioprotetor trealose na cicatrização epitelial da córnea após reticulação corneana para ceratocone
Sethi et al. A COMPARATIVE STUDY OF CONJUCTIVAL AUTOGRAFT IN PRIMARY AND RECURRENT PTERYGIUM IN SOUTHERN PART OF ODISHA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210127

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210322

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210323

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210409

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210413

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220201

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220817

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221213

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230110

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230110